

Special Issue

Urologic Oncology: Biomarkers and Targeted Therapies

Message from the Guest Editor

Urological malignancies, including prostate, urothelial, renal, and testicular cancers, pose significant challenges to patients due to their heterogeneity and variable responses to treatment. While traditional approaches can lead to suboptimal outcomes and unnecessary toxicity, new targeted therapies may represent a paradigm shift, offering personalised strategies tailored to the unique molecular profiles of tumors and patients. This Special Issue aims to bring together the latest advances in the discovery, validation, and clinical application of prognostic approaches and monitoring biomarkers for uro-oncology targeted therapies. From genomic and proteomic signatures (taking advantage of recent advances in machine learning and artificial intelligence) to circulating tumor cells and imaging biomarkers, each contribution will provide new insights into treatment response prediction, prognosis estimation, and therapy resistance mechanisms.

Guest Editor

Dr. Razvan Bardan

1. Department of Urology, Victor Babes University of Medicine and Pharmacy, 300041 Timișoara, Romania
2. Department of Urology, Clinical Emergency County Hospital, 300723 Timișoara, Romania

Deadline for manuscript submissions

closed (31 October 2024)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/200039

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).